--- title: "Director Of Icon Makes $138K Sale" type: "News" locale: "en" url: "https://longbridge.com/en/news/295817871.md" description: "John Climax, Director at Icon (NASDAQ:ICLR), sold 841 shares worth $138,168 on August 12. Icon's stock traded at $165.12, down 1.23%. The company reported 1.2% revenue growth as of June 30, 2026, lagging peers. Financial metrics include a 23.23% gross margin, EPS of 0.94, and a debt-to-equity ratio of 0.37. Valuation indicators show a high P/E ratio of 257.09 but lower P/S and EV/EBITDA ratios compared to industry averages." datetime: "2026-08-13T15:03:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295817871.md) - [en](https://longbridge.com/en/news/295817871.md) - [zh-HK](https://longbridge.com/zh-HK/news/295817871.md) generator: "portal-rs" --- # Director Of Icon Makes $138K Sale Making a noteworthy insider sell on August 12, **DR JOHN CLIMAX**, Director at **Icon** (NASDAQ:ICLR), is reported in the latest SEC filing. **What Happened:** CLIMAX opted to sell 841 shares of **Icon**, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The transaction's total worth stands at $138,168. Tracking the Thursday's morning session, **Icon** shares are trading at $165.12, showing a down of 1.23%. ### Delving into Icon's Background Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market. ### A Deep Dive into Icon's Financials **Revenue Growth:** Icon's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2026, the company achieved a revenue growth rate of approximately **1.2%**. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector. **Exploring Profitability:** - Gross Margin: The company shows a low gross margin of 23.23%, suggesting potential challenges in cost control and profitability compared to its peers. - Earnings per Share (EPS): Icon's EPS reflects a decline, falling below the industry average with a current EPS of 0.94. **Debt Management:** Icon's debt-to-equity ratio is below the industry average at **0.37**, reflecting a lower dependency on debt financing and a more conservative financial approach. **Navigating Market Valuation:** - Price to Earnings (P/E) Ratio: Icon's current Price to Earnings (P/E) ratio of 257.09 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment. - Price to Sales (P/S) Ratio: The P/S ratio of 1.56 is lower than the industry average, implying a discounted valuation for Icon's stock in relation to sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry averages at 23.22, Icon could be considered undervalued. **Market Capitalization Perspectives:** The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale. ### Why Insider Activity Matters in Finance Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering. In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction. Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock. Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors. ### A Deep Dive into Insider Transaction Codes Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** signifies a sale. Transaction code **C** denotes the conversion of an option, and transaction code **A** signifies a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Icon's Insider Trades. *This article was generated by Benzinga's automated content engine and reviewed by an editor.* ### Related Stocks - [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md) ## Related News & Research - [ICON announces availability of ICON Cares 2025 ESG report](https://longbridge.com/en/news/296491257.md) - [ICON plc Raises $2.15 Billion in Senior Notes to Refinance Secured Debt](https://longbridge.com/en/news/296253678.md) - [ICON sells USD 2.15 billion senior unsecured notes in three-part offering](https://longbridge.com/en/news/296236277.md) - [ICON Energy Maintained at Buy as Robust Dry Bulk Fundamentals Support Unchanged $3 Price Target](https://longbridge.com/en/news/296388659.md) - [ICON (ICLR) Could Be 13% Overvalued On Q1 Earnings And Repeated Outlook](https://longbridge.com/en/news/291799926.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**